

Othman Al-Sawaf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9576377/publications.pdf>

Version: 2024-02-01

67
papers

2,278
citations

394421

19
h-index

223800

46
g-index

71
all docs

71
docs citations

71
times ranked

2737
citing authors

#	ARTICLE	IF	CITATIONS
1	The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2022, 139, 177-187.	1.4	40
2	The role of minimal residual disease in chronic lymphocytic leukemia.. <i>Clinical Advances in Hematology and Oncology</i> , 2022, 20, 97-103.	0.3	0
3	Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial. <i>Leukemia</i> , 2022, 36, 2125-2128.	7.2	4
4	Richter transformation in chronic lymphocytic leukemia (CLL)â€”a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. <i>Leukemia</i> , 2021, 35, 169-176.	7.2	55
5	Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial. <i>Haematologica</i> , 2021, 106, 543-554.	3.5	12
6	Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> ,the, 2021, 9, 522-532.	10.7	195
7	Durable remissions following combined targeted therapy in patients with CLL harboring <i>TP53</i> deletions and/or mutations. <i>Blood</i> , 2021, 138, 1805-1816.	1.4	7
8	Health-related quality of life with fixed-duration venetoclax+obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 <i>CLL14</i> trial. <i>American Journal of Hematology</i> , 2021, 96, 1112-1119.	4.1	5
9	Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 775-791.	2.2	8
10	Using DNA sequencing data to quantify T cell fraction and therapy response. <i>Nature</i> , 2021, 597, 555-560.	27.8	36
11	Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. <i>American Journal of Hematology</i> , 2021, 96, 1679-1705.	4.1	150
12	Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized <i>CLL14</i> Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 4049-4060.	1.6	74
13	Acalabrutinib monotherapy in patients with Richter transformation. <i>Lancet Haematology</i> ,the, 2021, 8, e868-e870.	4.6	0
14	Pooled Analysis of First-Line Treatment with Targeted Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Aged 80 Years and Older. <i>Blood</i> , 2021, 138, 1552-1552.	1.4	1
15	ReVenC: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021, 138, 2634-2634.	1.4	4
16	<i>TP53</i> mutations in CLL: does frequency matter?. <i>Blood</i> , 2021, 138, 2600-2601.	1.4	2
17	Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy. <i>Leukemia</i> , 2020, 34, 1177-1181.	7.2	6
18	Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 357-362.	2.5	22

#	ARTICLE	IF	CITATIONS
19	Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1188-1200.	10.7	208
20	Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. <i>Blood</i> , 2020, 135, 2402-2412.	1.4	83
21	Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. <i>Leukemia</i> , 2020, 34, 2038-2050.	7.2	38
22	High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia. <i>Blood</i> , 2020, 135, 866-870.	1.4	30
23	Current Perspectives on Therapy for Chronic Lymphocytic Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 320-329.	3.8	16
24	Bendamustine Followed By Obinutuzumab and Idelalisib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BCG Trial of the German CLL Study Group (GCLLSG). <i>Blood</i> , 2020, 136, 21-23.	1.4	3
25	Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial. <i>Blood</i> , 2020, 136, 22-23.	1.4	20
26	Severe Infections in Patients with Chronic Lymphocytic Leukemia Treated with (Immuno-)Chemotherapy: A Pooled Analysis of Gcllsg Trials. <i>Blood</i> , 2020, 136, 18-19.	1.4	2
27	Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 8027-8027.	1.6	4
28	FIXED-DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES. <i>Hematological Oncology</i> , 2019, 37, 82-84.	1.7	0
29	GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORABMUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY Best abstract submitted by a young investigator / travel grant recipient. <i>Hematological Oncology</i> , 2019, 37, 84-86.	1.7	3
30	Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL). <i>American Journal of Hematology</i> , 2019, 94, 1002-1006.	4.1	5
31	Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. <i>New England Journal of Medicine</i> , 2019, 380, 2225-2236.	27.0	599
32	Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, e224-e226.	3.5	6
33	HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIAL. <i>Hematological Oncology</i> , 2019, 37, 104-106.	1.7	1
34	IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE-BLIND RANDOMIZED CLL12 TRIAL. <i>Hematological Oncology</i> , 2019, 37, 38-40.	1.7	28
35	CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. <i>Leukemia</i> , 2019, 33, 1161-1172.	7.2	38
36	Management of an adult patient with sickle cell disease and acute chest syndrome by veno-venous extracorporeal membrane oxygenation. <i>Annals of Hematology</i> , 2019, 98, 789-791.	1.8	9

#	ARTICLE	IF	CITATIONS
37	Pelvic cellulitis caused by Raoultella planticola in a neutropenic patient. Journal of Infection and Chemotherapy, 2019, 25, 298-301.	1.7	2
38	Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial. Blood, 2019, 134, 36-36.	1.4	18
39	Rapid Improvement of Patient-Reported Outcomes with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated CLL and Coexisting Conditions: A Prospective Analysis from the CLL14 Trial. Blood, 2019, 134, 4305-4305.	1.4	2
40	Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial. Blood, 2019, 134, 4315-4315.	1.4	3
41	Initial Therapy of Chronic Lymphocytic Leukemia. Hematologic Malignancies, 2019, , 79-96.	0.2	2
42	Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD ^{â€}) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities.. Journal of Clinical Oncology, 2019, 37, 7502-7502.	1.6	1
43	Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL): Final Results of the CLL2-BIG Trial of the German CLL Study Group (GCLLSG). Blood, 2019, 134, 3046-3046.	1.4	2
44	Outcome of patients aged 80Âyears or older treated for chronic lymphocytic leukaemia. British Journal of Haematology, 2018, 183, 727-735.	2.5	7
45	Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2018, 19, 1215-1228.	10.7	94
46	Durable Remissions after Discontinuation of Combined Targeted Treatment in Patients with Chronic Lymphocytic Leukemia (CLL) Harboring a High-Risk Genetic Lesion (del(17p)/TP53 Mutation). Blood, 2018, 132, 694-694.	1.4	16
47	Comparison of different phase II studies using sequential combinations of targeted agents for treating chronic lymphocytic leukemia.. Journal of Clinical Oncology, 2018, 36, 7513-7513.	1.6	0
48	Obesity Negatively Impacts Outcome in Female Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR): An Analysis of Three Phase III Studies of the German CLL Study Group (GCLLSG). Blood, 2018, 132, 4429-4429.	1.4	0
49	Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review. Therapeutic Advances in Hematology, 2017, 8, 197-205.	2.5	9
50	Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood, 2017, 129, 2702-2705.	1.4	108
51	Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology,the, 2017, 4, e475-e486.	4.6	45
52	BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G) AND VENETOCLAX (A) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2âBAG TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG). Hematological Oncology, 2017, 35, 25-27.	1.7	6
53	CHARACTERISTICS, TREATMENT, AND OUTCOMES OFÂ80 YEAR OLD PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ENROLLED TO PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP. Hematological Oncology, 2017, 35, 99-100.	1.7	0
54	Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group. Leukemia, 2017, 31, 2251-2253.	7.2	6

#	ARTICLE	IF	CITATIONS
55	Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial. <i>European Journal of Haematology</i> , 2017, 98, 254-262.	2.2	9
56	Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume11, 295-304.	4.3	15
57	Targeted Therapy of CLL. <i>Oncology Research and Treatment</i> , 2016, 39, 768-778.	1.2	9
58	Low Incidence of Tumor Lysis Syndromes (TLS) and Infusion Related Reactions (IRR) in the CLL2-Bag Trial Evaluating a Sequential Treatment of Bendamustine (B), Obinutuzumab (GA101, G) and Venetoclax (ABT-199, A) in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Safety Results of a Phase-II-Trial of the German CLL Study Group (GCLLSG). <i>Blood</i> , 2016, 128, 2044-2044.	1.4	4
59	Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323). <i>Blood</i> , 2016, 128, 2054-2054.	1.4	8
60	Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group). <i>Blood</i> , 2016, 128, 229-229.	1.4	12
61	Impact of Gender on Outcome after Chemoimmunotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) or Bendamustine Plus Rituximab (BR) in Patients with Chronic Lymphocytic Leukemia (CLL): A Meta-Analysis of Three Phase II/III Studies of the German CLL Study Group (GCLLSG). <i>Blood</i> , 2016, 128, 4394-4394.	1.4	1
62	Progression By Lymphocytosis Correlates with Favourable Long-Term Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2016, 128, 4352-4352.	1.4	0
63	Nrf2 in health and disease: current and future clinical implications. <i>Clinical Science</i> , 2015, 129, 989-999.	4.3	101
64	Nrf2 augments skeletal muscle regeneration after ischaemia-reperfusion injury. <i>Journal of Pathology</i> , 2014, 234, 538-547.	4.5	48
65	Nrf2 Protects Against TWEAK-mediated Skeletal Muscle Wasting. <i>Scientific Reports</i> , 2014, 4, 3625.	3.3	19
66	A Novel Laser-Doppler Flowmetry Assisted Murine Model of Acute Hindlimb Ischemia-Reperfusion for Free Flap Research. <i>PLoS ONE</i> , 2013, 8, e66498.	2.5	13
67	Pharmacokinetics and Exposure-Response Analysis of Venetoclax+Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial. <i>Advances in Therapy</i> , 0, , .	2.9	0